Biodegradable polyethylene glycol based water-insoluble hydrogels

Patent metadata

Field	Value
Publication number	US-11559482-B2
Application number	US-201013387971-A
Country	US
Kind code	B2
Filing date	Jul 30, 2010
Priority date	Jul 31, 2009
Publication date	Jan 24, 2023
Grant date	Jan 24, 2023

Abstract

The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.

First claim

The invention claimed is:

1. A biodegradable poly(ethylene glycol) based water-insoluble hydrogel consisting of:
backbone moieties which are interconnected by hydrolytically degradable bonds;
wherein the backbone moieties are linked together through crosslinker moieties, each crosslinker moiety being terminated by at least two of the hydrolytically degradable bonds; and
wherein each backbone moiety has a molecular weight in the range of from 1 kDa to 20 kDa and has the structure:
C*(A-Hyp) x
wherein:
C* is a branching core consisting of in bound form an oligoalcohol or polyalcohol;
A is a poly(ethylene glycol) based polymeric chain;
Hyp is a hyperbranched dendritic moiety consisting of:
reactive functional groups;
degradable interconnected functional groups, each degradable interconnected functional group being connected to one of the crosslinker moieties and consisting of one of the hydrolytically degradable bonds; and
lysine in bound form; and

x is an integer of from 3 to 16, so that each backbone moiety has at least 6 reactive functional groups and 6 degradable interconnected functional groups;

wherein the hydrogel is in the form of microparticles; and
wherein the hydrolytically degradable bonds include at least one bond selected from the group consisting of acetals, carboxylic anhydrides, esters, imines, hydrazones, maleamic acid amides, ortho esters, phosphamides, phosphoesters, phosphosilyl esters, silyl esters, sulfonic esters, aromatic carbamates, and combinations thereof.

2. The biodegradable hydrogel of claim 1 ;
wherein each crosslinker moiety has a molecular weight in the range of from 0.5 kDa to 5 kDa; and
wherein each crosslinker moiety is PEG based.

3. The biodegradable hydrogel of claim 1 ;
wherein each backbone moiety comprises in sum at least 16 interconnected biodegradable and reactive functional groups.

4. A conjugate comprising:
the hydrogel of claim 1 ;
wherein the hydrogel additionally carries permanent linkages to spacer molecules or blocking groups or combinations thereof.

5. A conjugate comprising:
the hydrogel of claim 1 ;
wherein the hydrogel additionally carries permanent linkages to ligands or chelating groups.

6. A carrier-linked prodrug comprising:
the biodegradable hydrogel of claim 1 as carrier;
wherein a number of permanent linkages of the backbone moieties exist, each with a transient prodrug linker L to which a biologically active moiety D is covalently attached.

7. The carrier-linked prodrug of claim 6 ;
wherein the transient linkage between D and L is a carbamate, carbonate, amide, or ester linkage.

8. The carrier-linked prodrug of claim 6 ;
wherein the transient prodrug linker L comprises a moiety L 1 , which is substituted with a moiety L 2 ; and
wherein L 2 is bound to a carrier group Z, which is the hydrogel.

9. The carrier-linked prodrug of claim 8 ;
wherein L 2 is attached to Z via a terminal group having the following structure:

wherein the dashed lines indicate the attachment to L 2 and Z, respectively.

10. The hydrogel of claim 1 ;
wherein the microparticles are obtained by comminution by a mechanical process.

Assignees

• Rau Harald
• Hersel Ulrich
• Krusch Mathias
• Vetter Dirk
• Voigt Tobias
• Ascendis Pharma As

Inventors

• Rau Harald
• Hersel Ulrich
• Krusch Mathias
• Vetter Dirk
• Voigt Tobias

Classifications

• A61K47/6903 Primary

  the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

• A61K9/0024 Primary

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• C08J3/075

  Macromolecular gels · CPC title

• A61K47/60

  the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title